What I Saw at the 2026 APC Owner Summit and Where Compounding Goes Next

What I Saw at the 2026 APC Owner Summit and Where Compounding Goes Next

By: Shaun Noorian, Founder and CEO, Empower Pharmacy 

Recently, members of the Empower team joined me at the 2026 APC Owner Summit in Austin, alongside other leaders and operators shaping the future of compounding.

What was abundantly clear from hour one is that this industry knows what it’s building and why.

Every conversation, in sessions and in the hallways between them, had a quality I don’t always see at industry events. Not enthusiasm for its own sake, but conviction grounded in the work. Pharmacy owners, operators, clinicians, and builders rolling up their sleeves together to make what we know to be true a reality: personalized medicine is where healthcare is going, and compounding is central to how it gets there.

Here are my biggest takeaways from the conference:

The entire system must adapt around the patient, not the other way around.

For years, much of compounding has been positioned as a gap-filler, something that exists because standardized products fall short. However, where we’ve seen real traction and meaningful advancement is among those who recognize that patients are more informed, and providers are seeking more precise treatment options.

The universal truth is that personalization is no longer niche. The summit made clear that the compounding industry is not waiting for the broader healthcare system to catch up. We’re building the infrastructure that will pull it forward.

The next chapter will be defined by trust at scale.

Access to individualized treatments optimized for patient care and outcomes has always been the central fight in compounding, and it remains one. But as demand grows, the conversation is expanding to address the question of scale: How can personalized medicine be delivered to every patient and provider who needs it without compromising quality, safety, or consistency?

This is a question of technical excellence and clinical know-how. I’ve learned over the years that there are several key requirements to achieving that goal, and many of these were central to our conversations in Austin: systems must be optimized for targeted production, capacity, and timely delivery. Quality must be verifiable, not just claimed. Transparency is mandatory across the supply chain. Clinical alignment between pharmacists and providers is essential to ensure personalized therapies are part of a coordinated care model, not a parallel one.

The operators who solve for that, who build reliable systems that hold at volume, will define what this industry looks like in the next decade.

Empower has a responsibility to help set that standard.

We’ve never been satisfied to stand back and benefit from the growth of compounding. Core to our purpose and operating principles is driving innovation and collaboration that raise the bar for what a pharmacy can be.

That means continuously deepening integration with providers, maintaining a long-term commitment to quality and compliance that goes beyond minimum requirements, and expanding access in a way that improves outcomes, not just volume.

I left Austin more optimistic than I’ve been in a long time. Not because the challenges are getting smaller, but because the industry is getting sharper, more aligned, and more serious about the responsibility in front of it.

The future of compounding isn’t something we’re waiting to see. It’s something we’re already building.